Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer.

Zivanovic O, Sima CS, Iasonos A, Bell-McGuinn KM, Sabbatini PJ, Leitao MM, Levine DA, Gardner GJ, Barakat RR, Chi DS.

Gynecol Oncol. 2009 Nov;115(2):209-14. doi: 10.1016/j.ygyno.2009.06.038. Epub 2009 Aug 7.

2.

The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.

Zivanovic O, Sima CS, Iasonos A, Hoskins WJ, Pingle PR, Leitao MM Jr, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS.

Gynecol Oncol. 2010 Mar;116(3):351-7. doi: 10.1016/j.ygyno.2009.11.022.

3.

Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.

Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C, Schorge JO, Del Carmen MG, Matulonis UA, Horowitz NS.

Gynecol Oncol. 2012 May;125(2):362-6. doi: 10.1016/j.ygyno.2012.02.006. Epub 2012 Feb 12.

PMID:
22333992
4.

The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.

Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Huh WK, Straughn JM Jr.

Gynecol Oncol. 2009 Aug;114(2):242-5. doi: 10.1016/j.ygyno.2009.04.019. Epub 2009 May 17.

PMID:
19447480
5.

Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?

Perri T, Ben-Baruch G, Kalfon S, Beiner ME, Helpman L, Hogen LB, Shapira-Frommer R, Korach J.

Gynecol Oncol. 2013 Oct;131(1):27-31. doi: 10.1016/j.ygyno.2013.07.093. Epub 2013 Jul 21.

PMID:
23880152
6.

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.

Gynecol Oncol. 2007 Jan;104(1):176-80. Epub 2006 Sep 25.

PMID:
16996584
7.

[Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].

Mu T, Li XP, Wang JL, Wang SJ, Wang Y, Sun XL, Cui H, Wei LH.

Zhonghua Fu Chan Ke Za Zhi. 2012 Aug;47(8):566-70. Chinese.

PMID:
23141174
8.
9.

Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.

Eisenhauer EL, Tew WP, Levine DA, Lichtman SM, Brown CL, Aghajanian C, Huh J, Barakat RR, Chi DS.

Gynecol Oncol. 2007 Aug;106(2):381-7. Epub 2007 May 16.

PMID:
17509673
10.

Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.

Kang WD, Choi HS, Kim SM.

Gynecol Oncol. 2010 Jan;116(1):57-60. doi: 10.1016/j.ygyno.2009.09.019. Epub 2009 Oct 9.

PMID:
19818996
11.

[Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].

Wang XY, Ye J, Feng SW, Lü WG, Wan XY, Xie X.

Zhonghua Fu Chan Ke Za Zhi. 2010 Nov;45(11):813-6. Chinese.

PMID:
21211277
12.

Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortium.

Melmer A, Fineder L, Lamina C, Kollerits B, Dieplinger B, Braicu I, Sehouli J, Cadron I, Vergote I, Mahner S, Zeimet AG, Castillo-Tong DC, Ebenbichler CF, Zeillinger R, Dieplinger H.

Gynecol Oncol. 2013 Jan;128(1):38-43. doi: 10.1016/j.ygyno.2012.09.032. Epub 2012 Oct 9.

PMID:
23063758
13.

The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.

Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS.

Gynecol Oncol. 2008 Feb;108(2):276-81. Epub 2007 Dec 11.

PMID:
18063020
14.

Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.

Zwakman N, van de Laar R, Van Gorp T, Zusterzeel PL, Snijders MP, Ferreira I, Massuger LF, Kruitwagen RF.

J Gynecol Oncol. 2017 Jan;28(1):e7. doi: 10.3802/jgo.2017.28.e7. Epub 2016 Sep 12.

15.

Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.

Landrum LM, Moore KN, Myers TK, Lanneau GS Jr, McMeekin DS, Walker JL, Gold MA.

Gynecol Oncol. 2009 Feb;112(2):337-41. doi: 10.1016/j.ygyno.2008.10.009. Epub 2008 Nov 28.

PMID:
19041126
16.
17.

Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer.

Prat A, Parera M, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, Martinez-Palones JM, Roxana I, Baselga J, Del Campo JM.

Ann Oncol. 2008 Feb;19(2):327-31. Epub 2007 Dec 6.

PMID:
18065408
18.

Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report.

Skaznik-Wikiel ME, Sukumvanich P, Beriwal S, Zorn KK, Kelley JL, Richard SD, Krivak TC.

Int J Gynecol Cancer. 2011 Aug;21(6):1013-7. doi: 10.1097/IGC.0b013e31821ce903.

PMID:
21792011
19.

Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer?

Le T, Faught W, Hopkins L, Fung-Kee-Fung M.

J Obstet Gynaecol Can. 2009 Jan;31(1):42-7.

PMID:
19208282
20.

The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.

Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp T, Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong DC, Zeillinger R, Zeimet AG, Vergote I.

Gynecol Oncol. 2013 Oct;131(1):15-20. doi: 10.1016/j.ygyno.2013.07.086. Epub 2013 Jul 20.

PMID:
23877013

Supplemental Content

Support Center